|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 90.59 USD | -1.67% |
|
-3.65% | +11.83% |
| Capitalization | 115B 109B 101B 89.78B 162B 9,743B 178B 1,252B 462B 3,998B 431B 422B 17,341B | P/E ratio 2024 * |
980x | P/E ratio 2025 * | 16x |
|---|---|---|---|---|---|
| Enterprise value | 133B 125B 116B 104B 187B 11,244B 205B 1,444B 533B 4,614B 498B 487B 20,013B | EV / Sales 2024 * |
4.68x | EV / Sales 2025 * | 4.53x |
| Free-Float |
-
| Yield 2024 * |
3.39% | Yield 2025 * | 3.56% |
More valuation ratios
* Estimated data
More news
Last Transcript: Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | -1.67% | ||
| 1 week | -2.15% | ||
| Current month | -2.15% | ||
| 1 month | -6.19% | ||
| 3 months | +15.08% | ||
| 6 months | +40.02% | ||
| Current year | +11.83% |
1 week
89.86
94.39
1 month
86.0898.90
Current year
62.0798.90
1 year
62.0798.90
3 years
57.1798.90
5 years
56.5698.90
10 years
56.56123.37
| Director | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 2019-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 2019-10-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 2021-04-11 |
| Manager | Title | Age | Since |
|---|---|---|---|
Kelly Kramer
BRD | Director/Board Member | 56 | 2016-08-18 |
| Director/Board Member | 71 | 2017-12-31 | |
| Director/Board Member | 70 | 2018-05-08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 380 M€ | +8.97% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -1.67% | -2.15% | +14.64% | +29.95% | 115B | ||
| -2.80% | +1.03% | +34.37% | +228.90% | 744B | ||
| -0.41% | +3.30% | +17.01% | +111.83% | 493B | ||
| +0.19% | -3.49% | -3.12% | -8.97% | 359B | ||
| +0.22% | -3.48% | +18.28% | +44.88% | 311B | ||
| +0.68% | +2.12% | +0.04% | +41.77% | 261B | ||
| +0.08% | +0.67% | +1.54% | -31.03% | 235B | ||
| +0.45% | +0.85% | +5.73% | +29.19% | 211B | ||
| -0.48% | -4.17% | +5.50% | +19.46% | 205B | ||
| +1.85% | -1.85% | +3.16% | +30.02% | 147B | ||
| Average | -0.46% | -0.51% | +9.71% | +49.60% | 308.06B | |
| Weighted average by Cap. | -0.84% | +0.50% | +14.08% | +83.68% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 28.3B 26.75B 24.82B 22.13B 39.97B 2,402B 43.79B 309B 114B 985B 106B 104B 4,275B | 28.31B 26.76B 24.83B 22.14B 39.98B 2,402B 43.8B 309B 114B 986B 106B 104B 4,276B |
| Net income | 259M 245M 227M 203M 366M 22B 401M 2.83B 1.04B 9.03B 974M 952M 39.16B | 6.92B 6.54B 6.07B 5.41B 9.77B 587B 10.71B 75.44B 27.85B 241B 25.99B 25.42B 1,045B |
| Net Debt | 17.69B 16.72B 15.51B 13.83B 24.98B 1,501B 27.36B 193B 71.18B 616B 66.42B 64.97B 2,671B | 13.33B 12.6B 11.69B 10.42B 18.82B 1,131B 20.62B 145B 53.64B 464B 50.05B 48.96B 2,013B |
More financial data
* Estimated data
Employees
18,000
Sector
Pharmaceuticals
Calendar
2024-12-12
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-09 | 90.59 $ | -1.67% | 7,396,100 |
| 24-12-06 | 92.13 $ | -1.35% | 4,470,730 |
| 24-12-05 | 93.39 $ | +1.97% | 12,428,734 |
| 24-12-04 | 91.59 $ | -0.97% | 9,124,340 |
| 24-12-03 | 92.49 $ | -1.63% | 5,532,434 |
Delayed Quote Nasdaq, December 09, 2024 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
90.59USD
Average target price
97.85USD
Spread / Average Target
+8.01%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GILD Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition